Business Description
Ipsen SA
NAICS : 325412
ISIN : FR0010259150
Share Class Description:
LTS:0MH6: Ordinary SharesCompare
Compare
Traded in other countries / regions
IPN.France0MH6.UKIPSEY.USAI7G.GermanyIPN.AustriaIPN.Mexico IPO Date
2010-04-01Description
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders. Over the past nearly 100 years, Ipsen has shifted its focus to specialty care, which comprises the vast majority of its total revenue. In February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 25 drugs in 115 countries.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.73 | |||||
| Equity-to-Asset | 0.61 | |||||
| Debt-to-Equity | 0.08 | |||||
| Debt-to-EBITDA | 0.29 | |||||
| Interest Coverage | 11.53 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 3.31 | |||||
| Beneish M-Score | -2.26 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 7.2 | |||||
| 3-Year EBITDA Growth Rate | 3.8 | |||||
| 3-Year EPS without NRI Growth Rate | 7.8 | |||||
| 3-Year FCF Growth Rate | 2.7 | |||||
| 3-Year Book Growth Rate | 21.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 6.26 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 5.97 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 55.95 | |||||
| 9-Day RSI | 52.61 | |||||
| 14-Day RSI | 50.74 | |||||
| 3-1 Month Momentum % | 4.81 | |||||
| 6-1 Month Momentum % | -8.14 | |||||
| 12-1 Month Momentum % | 8.28 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.17 | |||||
| Quick Ratio | 0.99 | |||||
| Cash Ratio | 0.32 | |||||
| Days Inventory | 181.83 | |||||
| Days Sales Outstanding | 67.76 | |||||
| Days Payable | 426.25 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.09 | |||||
| Dividend Payout Ratio | 0.16 | |||||
| 3-Year Dividend Growth Rate | 6.3 | |||||
| Forward Dividend Yield % | 1.09 | |||||
| 5-Year Yield-on-Cost % | 1.35 | |||||
| Shareholder Yield % | 3.92 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 82.01 | |||||
| Operating Margin % | 17.08 | |||||
| Net Margin % | 19.83 | |||||
| FCF Margin % | 12.37 | |||||
| ROE % | 19.33 | |||||
| ROA % | 11.34 | |||||
| ROIC % | 10.41 | |||||
| 3-Year ROIIC % | -14.95 | |||||
| ROC (Joel Greenblatt) % | 146.54 | |||||
| ROCE % | 18.96 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 13.43 | |||||
| Forward PE Ratio | 10.81 | |||||
| PE Ratio without NRI | 14.9 | |||||
| Shiller PE Ratio | 22.65 | |||||
| Price-to-Owner-Earnings | 12.84 | |||||
| PEG Ratio | 0.6 | |||||
| PS Ratio | 2.67 | |||||
| PB Ratio | 2.37 | |||||
| Price-to-Tangible-Book | 18.79 | |||||
| Price-to-Free-Cash-Flow | 21.57 | |||||
| Price-to-Operating-Cash-Flow | 10.15 | |||||
| EV-to-EBIT | 10.48 | |||||
| EV-to-Forward-EBIT | 8.94 | |||||
| EV-to-EBITDA | 8.35 | |||||
| EV-to-Forward-EBITDA | 6.53 | |||||
| EV-to-Revenue | 2.57 | |||||
| EV-to-Forward-Revenue | 2.38 | |||||
| EV-to-FCF | 20.82 | |||||
| Price-to-GF-Value | 0.93 | |||||
| Price-to-Projected-FCF | 0.92 | |||||
| Price-to-DCF (Earnings Based) | 0.39 | |||||
| Price-to-DCF (FCF Based) | 0.58 | |||||
| Price-to-Median-PS-Value | 0.92 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.49 | |||||
| Price-to-Graham-Number | 3.16 | |||||
| Earnings Yield (Greenblatt) % | 9.54 | |||||
| FCF Yield % | 4.69 | |||||
| Forward Rate of Return (Yacktman) % | 25.73 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ipsen SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 3,435.1 | ||
| EPS (TTM) (€) | 8.16 | ||
| Beta | 0.71 | ||
| 3-Year Sharpe Ratio | 0.3 | ||
| 3-Year Sortino Ratio | 0.49 | ||
| Volatility % | 20 | ||
| 14-Day RSI | 50.74 | ||
| 14-Day ATR (€) | 2.097017 | ||
| 20-Day SMA (€) | 109.265 | ||
| 12-1 Month Momentum % | 8.28 | ||
| 52-Week Range (€) | 99.5 - 126.3 | ||
| Shares Outstanding (Mil) | 82.71 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ipsen SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ipsen SA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Ipsen SA Frequently Asked Questions
What is Ipsen SA(LTS:0MH6)'s stock price today?
The current price of LTS:0MH6 is €110.25. The 52 week high of LTS:0MH6 is €126.30 and 52 week low is €99.50.
When is next earnings date of Ipsen SA(LTS:0MH6)?
The next earnings date of Ipsen SA(LTS:0MH6) is 2025-02-07 Est..
Does Ipsen SA(LTS:0MH6) pay dividends? If so, how much?
The Dividend Yield %  of Ipsen SA(LTS:0MH6) is 1.09% (As of Today), Highest Dividend Payout Ratio of Ipsen SA(LTS:0MH6) was 30.36. The lowest was 0.11. And the median was 0.16. The  Forward Dividend Yield % of Ipsen SA(LTS:0MH6) is 1.09%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers